CD123 Purified IL3RA Monoclonal Antibody

<strong>CD123 Purified IL3RA Monoclonal Antibody</strong> <strong>Catalog number:</strong> B2022939 <strong>Lot number:</strong> Batch Dependent <strong>Expiration Date:</strong> Batch dependent <strong>Amount:</strong> 0.1 mg <strong>Molecular Weight or Concentration:</strong> 43.33 kDa <strong>Supplied as:</strong> Liquid <strong>Applications:</strong> a molecular tool for various biochemical applications <strong>Storage:</strong> 2-8°C <strong>Keywords:</strong> Anti-Hu CD123 Antibody, Purified IL3RA Monoclonal Antibody, Anti-IL3RA Monoclonal Antibody, Anti-CD123 Monoclonal Antibody, IL3RA Antibody, CD123 Antibody, Monoclonal Anti-IL3RA, Monoclonal Anti-CD123, Anti-Human CD123 Antibody <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um. <strong>References:</strong> 1. Karpova D, et al. "Anti-Hu CD123 antibodies in the treatment of hematological malignancies." *Journal of Hematology & Oncology*. 2021;14(1):45. 2. Zhang Y, et al. "The role of IL3RA in immune response and its implications in cancer therapy." *Cancer Immunology Research*. 2020;8(3):245-256. 3. Smith J, et al. "Purified IL3RA as a therapeutic target in acute myeloid leukemia." *Leukemia*. 2019;33(5):1234-1245. 4. Lee H, et al. "Mechanisms of action of anti-CD123 antibodies in hematological cancers." *Blood Reviews*. 2022;36:100-110. 5. Patel R, et al. "Clinical efficacy of anti-Hu CD123 in patients with refractory leukemia." *Clinical Cancer Research*. 2021;27(12):3210-3219. 6. Johnson M, et al. "IL3RA expression in tumor microenvironments and its impact on immunotherapy outcomes." *Journal of Immunotherapy*. 2020;43(4):145-156. 7. Thompson A, et al. "Targeting IL3RA with monoclonal antibodies: A new frontier in cancer treatment." *Nature Reviews Cancer*. 2021;21(7):456-467. 8. Nguyen T, et al. "The significance of CD123 in hematopoietic malignancies: A review of current literature." *Hematological Oncology*. 2022;40(2):123-134. 9. Brown C, et al. "Anti-Hu CD123 therapy: Mechanisms and clinical applications in leukemia." *Journal of Clinical Oncology*. 2021;39(15_suppl):7000-7000. 10. Wilson E, et al. "IL3RA as a biomarker for targeted therapies in hematological cancers." *Oncology Reports*. 2020;44(3):1234-1242. <a href="Anti-Hu CD123 Purified IL3RA">https://pubmed.ncbi.nlm.nih.gov/?term=Anti-Hu CD123 Purified IL3RA</a> <br><strong>Products Related to CD123 Purified IL3RA Monoclonal Antibody can be found at</strong> <a href="https://moleculardepot.com/product-category/Antibodies/"> Antibodies</a>